Letter From the Editors: A Question of Ownership
By Daniel D. Von Hoff, MD, and J. Lyle Bootman, PhD
Letter From the Editors
A Singleness of Purpose— A Spectrum of Expertise and Care— What Will the Future Bring?
J. Lyle Bootman, PhD Co-Editor
Daniel D. Von Hoff, MD Co-Editor
A Standing Ovation for a Change in How We Treat Patients With Cancer —Forever
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman PhD
Addressing the Quality Chasm for a New Health System in the 21st Century
By J. Lyle Bootman, PhD, and Daniel D. Von Hoff, MD
Are We Prepared for the Genomics Era?
By J. Lyle Bootma
Are You Ready For Some Ethics, Some Success, Some Cytoprotectants, and Some New Board Members?
By Daniel D. Von Hoff, MD, FACP, and J. Lyle Bootman, PhD
Lymphomas – The Diseases That Taught Us Monoclonal Antibodies Can Work
Right Tool, Right Time, Right Reason
By J. Lyle Bootman, PhD, and Daniel D. Von Hoff, MD, FACP
Letter to the Editor
AGGRAVATION OF SCHIZOPHRENIA BY CLOMIPRAMINE IN A PATIENT WITH COMORBID OBSESSIVE-COMPULSIVE DISORDER
LETTER TO THE EDITOR
GLUCOSE TESTING IN PATIENTS RECEIVING ANTIPSYCHOTIC
Lineamientos universales
Indíce de medicamentos para Latinoamérica
Long-Term Antidepressant Treatment
By Katia K. Delrahim, BA, Rachel Maddux, BA, and Mark Hyman Rapaport, MD
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
By Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O’Brien